|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0030705,
umls-concept:C0043157,
umls-concept:C0079488,
umls-concept:C0087111,
umls-concept:C0162643,
umls-concept:C0205164,
umls-concept:C0205175,
umls-concept:C0220938,
umls-concept:C1332828,
umls-concept:C1524063,
umls-concept:C1882417,
umls-concept:C2698872
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2004-9-16
|
|
pubmed:abstractText |
Proton pump inhibitors, metabolized by the polymorphic enzyme cytochrome P450 (CYP) 2C19, are essential drugs for Helicobacter pylori eradication. It was reported that patients with CYP2C19 wild type in Asia had lower eradication rates. This study tests the hypothesis that CYP2C19 wild type ( wt/wt ) in white patients is also associated with a higher probability of treatment failure.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0009-9236
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
76
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
201-9
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15371981-2-Pyridinylmethylsulfinylbenzimidazoles,
pubmed-meshheading:15371981-Adult,
pubmed-meshheading:15371981-Aged,
pubmed-meshheading:15371981-Aryl Hydrocarbon Hydroxylases,
pubmed-meshheading:15371981-Cohort Studies,
pubmed-meshheading:15371981-Drug Therapy, Combination,
pubmed-meshheading:15371981-European Continental Ancestry Group,
pubmed-meshheading:15371981-Female,
pubmed-meshheading:15371981-Genotype,
pubmed-meshheading:15371981-Helicobacter Infections,
pubmed-meshheading:15371981-Helicobacter pylori,
pubmed-meshheading:15371981-Humans,
pubmed-meshheading:15371981-Male,
pubmed-meshheading:15371981-Middle Aged,
pubmed-meshheading:15371981-Mixed Function Oxygenases,
pubmed-meshheading:15371981-Omeprazole,
pubmed-meshheading:15371981-Polymorphism, Genetic,
pubmed-meshheading:15371981-Treatment Failure
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori.
|
|
pubmed:affiliation |
Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D-70376 Stuttgart, Germany. matthias.schwab@ikp.stuttgart.de
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
